


Characteristic & Number (\%) of evaluations, N=211 & Count of unique studies, N=63\\
\hline
Type of comparison &  & \\
\hline
\hspace{1em}PCV7 vs NoVax & 24 (11\%) & 14\\
\hline
\hspace{1em}PCV10 vs NoVax & 77 (36\%) & 33\\
\hline
\hspace{1em}PCV13 vs NoVax & 65 (31\%) & 32\\
\hline
\hspace{1em}PCV13 vs PCV10 & 33 (16\%) & 24\\
\hline
\hspace{1em}Others & 12 (6\%) & 7\\
\hline
Number of doses &  & \\
\hline
\hspace{1em}Four & 74 (35\%) & 21\\
\hline
\hspace{1em}Three & 118 (56\%) & 41\\
\hline
\hspace{1em}One/two & 10 (5\%) & 4\\
\hline
\hspace{1em}Unknown & 9 (4\%) & 2\\
\hline
Study perspective &  & \\
\hline
\hspace{1em}Healthcare/payer & 114 (54\%) & 45\\
\hline
\hspace{1em}Societal & 97 (46\%) & 32\\
\hline
Income group &  & \\
\hline
\hspace{1em}Low & 18 (9\%) & 6\\
\hline
\hspace{1em}Lower-middle & 40 (19\%) & 17\\
\hline
\hspace{1em}Upper-middle & 153 (73\%) & 43\\
\hline
Included herd effects & 72 (34\%) & 29\\
\hline
Included serotype replacement & 40 (19\%) & 17\\
\hline
Pneumonia efficacy endpoint & 211 (100\%) & 63\\
\hline
IPD efficacy endpoint & 207 (98\%) & 61\\
\hline
Otitis media efficacy endpoint & 179 (85\%) & 54\\
\hline
Included budget impact analysis & 56 (27\%) & 14\\
\hline
Study decision &  & \\
\hline
\hspace{1em}Cost-saving & 26 (12\%) & 15\\
\hline
\hspace{1em}Cost-effective & 157 (74\%) & 49\\
\hline
\hspace{1em}Not cost-effective & 28 (13\%) & 14\\
\hline

